Company Overview
Company Type: Private Company
Website: abderatx.com
Number of Employees: -
Year Founded: 2020
Total Amount Raised (CAD mm)†: 199.64
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Abdera Therapeutics Inc., a precision oncology company, develops targeted radiation therapies for cancer. The company offers Radio Optimized Vector Engineering (ROVEr) platform that enables the company to engineer potential therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells. Abdera Therapeutics Inc. was incorporated in 2020 and is based in Vancouver, Canada with an additional location in Menlo Park, California.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Lyons-Williams, Lori M.
President, CEO & Director
Abrams, Michael J.
Co-Founder & Senior Adviser
Janes, Lana Elizabeth
Co-Founder & Senior Vice President of Operations and Innovation
Judge, Adam 
Co-founder & Senior Vice President of Research
McNealey, Jennifer Isacoff
Chief Financial Officer
Chiu, Kawa 
Chief Technical Officer
Parker, Kelly 
Senior Vice President of Human Resources
Armour, Alison A.
Interim Chief Medical Officer

Key Board Members
Name
Title
Nicholson, Garry A.
Chairman of the Board
Lyons-Williams, Lori M.
President, CEO & Director
Drewry, Joel 
Director
Harrison, Nancy Elizabeth
Director
Koehler, Maria 
Director
Walsh, Colin 
Director
Yamanaka, Yvonne 
Director


Primary Industry Classification
Biotechnology


Primary Office Location
1770 W 7th Ave 5th Floor | Vancouver, BC | V6J 4Z9 | Canada
Phone: 778-200-2999   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
adMare BioInnovations
Apr-20-2023
Minority
-
Venture
Amplitude Ventures
Apr-20-2023
Minority
-
Venture
Northview LifeSciences
Apr-20-2023
Minority
-
Venture
Qiming Venture Partners USA
Apr-20-2023
Minority
-
Venture
RTW Investments, LP
Apr-20-2023
Minority
-
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-20-2023
Apr-20-2023
Private Placement
Target
Abdera Therapeutics Inc.
Versant Venture Management, LLC,Amplitude Ventures,Northview LifeSciences,venBio LLC,Viking Global Investors LP,Qiming Venture Partners USA,RTW Investments, LP,adMare BioInnovations

142.00
Jan-22-2021
Jan-22-2021
Private Placement
Target
Abdera Therapeutics Inc.


6.29
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-05-2023
Company Conference Presentations
Abdera Therapeutics Inc. Presents at BIO International Convention 2023, Jun-05-2023
Apr-20-2023
Private Placements
Abdera Therapeutics Inc. announced that it has received $142 million in funding from a group of investors
Jan-22-2021
Private Placements
Abdera Therapeutics Inc. announced that it has received CAD 8 million in funding


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Nicholson, Garry A.
Chairman of the Board
778-200-2999
-

Lyons-Williams, Lori M.
President, CEO & Director
778-200-2999
-
lorimlyons@gmail.com
Drewry, Joel 
Director
778-200-2999
-

Harrison, Nancy Elizabeth
Director
778-200-2999
-

Koehler, Maria 
Director
778-200-2999
-

Walsh, Colin 
Director
778-200-2999
-
colin@qimingvc.com
Yamanaka, Yvonne 
Director
778-200-2999
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Lyons-Williams, Lori M.
President, CEO & Director
778-200-2999
-
lorimlyons@gmail.com
Abrams, Michael J.
Co-Founder & Senior Adviser
778-200-2999
-

Janes, Lana Elizabeth
Co-Founder & Senior Vice President of Operations and Innovation
778-200-2999
-

Judge, Adam 
Co-founder & Senior Vice President of Research
778-200-2999
-

McNealey, Jennifer Isacoff
Chief Financial Officer
778-200-2999
-

Chiu, Kawa 
Chief Technical Officer
778-200-2999
-

Parker, Kelly 
Senior Vice President of Human Resources
778-200-2999
-

Armour, Alison A.
Interim Chief Medical Officer
778-200-2999
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
